CTRI/2023/12/060772尚未招募4 期
Efficacy and safety of dapagliflozin vs sacubitril/valsartan among patients of heart failure with reduced ejection fraction: A randomized study. - NO
All India Institute Of Medical Sciences, Jodhpur0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Patients Age 18 year to 75 years of either sex.
- •2.Left Ventricular ejection fraction <40%
- •3.Patient having Heart failure belonging to NYHA class II-III
排除标准
- •1.Patient having Acute decompensated Heart failure.
- •2.Patient who have eGFR < 30ml/min/1.73m2 at screening visit.
- •3.Patient with history of intolerance to SGLT-2 inhibitor or ARNI (Angiotensin receptor-neprilysin inhibitor)
- •4.Patients having AST/ALT =3 times of normal range
- •5.Pregnant and lactating women.
- •6.Patient with recurrent Urinary Tract Infections.
- •7.Patient having recent Pyelonephritis.
研究者
相似试验
招募中
3 期
Safety and efficacy of Dapagliflozin and sitagliptin in elderly uncontrolled type 2 diabetes mellitus patientsCTRI/2023/06/053833Dr Mukku Venkata Pratap Reddy
招募中
不适用
Is Sacubitril-valsartan Superior to Dapagliflozin in Improving Myocardial Function PerformanceHeart FailureNCT06090487Ain Shams University30
尚未招募
4 期
To compare safety and effectiveness of combination of sacubitril and valsartan with telmisartan in patients suffering from heart failure.CTRI/2019/05/019284Dr Kunwar Shailen Dev Singh Guleria
进行中（未招募）
1 期
Effectiveness of Dapagliflozin + Saxagliptin to revert from a standard basalbolusinsulin treatment (BBIT) regimen to a basal supported oral therapy(BOT) in patients with Type 2 Diabetes – a randomised double-blindedstudy – a randomised double-blinded studyEUCTR2015-005740-34-DEniversitätsklinikum Tübingen4
已完成
不适用
The study of dapagliflozin versus sitagliptin treatment efficacy on preventing cardiovascular risk factors in type 2 DM patients (DIVERSITY-CVR study)Type 2 Diabetes MellitusJPRN-UMIN000028014the Japan Society for Patient Reported Outcome (PRO)340